How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Consumer Goods · Forecast 2027–2033
Synthesis Peptide for Cosmetic Application Market
- By Peptide Type: Signal Peptides, Carrier Peptides, Neurotransmitter Inhibitor Peptides, Enzyme Inhibitor Peptides, Hormonal Peptides
- By Application: Anti-aging Products, Skin Whitening Products, Moisturizers, Hair Care Products, Sun Care Products
- By Formulation Type: Creams and Lotions, Serums, Masks, Toners, Cleansers
- By End-user: Personal Care Industry, Professional Skin Care Clinics, Dermatology Clinics, Spa and Wellness Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Signal Peptides leads By Peptide Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Synthesis Peptide for Cosmetic Application Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Peptide Type 5
Application 5
Formulation Type 5
End-user 4
Companies profiled
Evonik Industries AG
Bachem Holding AG
CSPC Pharmaceutical Group Limited
PolyPeptide Group
Genscript Biotech Corporation
Sino Biological Inc.
PeptiDream Inc.
China Peptides Co. Ltd.
Thermo Fisher Scientific Inc.
Lonza Group AG
Almac Group
JPT Peptide Technologies GmbH
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Evonik Industries AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bachem Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →CSPC Pharmaceutical Group Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →PolyPeptide Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Genscript Biotech Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sino Biological Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →PeptiDream Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →China Peptides Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Thermo Fisher Scientific Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Lonza Group AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Almac Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →JPT Peptide Technologies GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →CordenPharma International GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →BASF SE
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sinerga S.p.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,411M by 2033 · 10.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Signal Peptides49.3
- Carrier Peptides7.1
- Neurotransmitter Inhibitor Peptides9.4
- Enzyme Inhibitor Peptides15.9
- Hormonal Peptides18.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,383M → $3,004M · 10.2%
Europe$963.8M → $2,085M · 10.1%
Asia Pacific$880.0M → $1,983M · 10.7%
Latin America$544.8M → $1,357M · 12.1%
Middle East and Africa$419.0M → $996.9M · 11.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.602026
10.612027
10.622028
10.632029
10.652030
10.652031
10.672032
10.672033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Evonik Industries AG20.3
- Bachem Holding AG7.7
- CSPC Pharmaceutical Group Limited10.7
- PolyPeptide Group12.4
- Genscript Biotech Corporation8.9
- Sino Biological Inc.12.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Peptide Type26.5%
Application36.0%
Formulation Type17.4%
End-user20.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.9
- Europe22.1
- Asia Pacific21.0
- Latin America14.4
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Evonik Industries AG | 88 | 75 | 81 | 79 | 78 | 95 | 83 |
| Bachem Holding AG | 69 | 70 | 74 | 80 | 90 | 85 | 78 |
| CSPC Pharmaceutical Group Limited | 67 | 82 | 70 | 80 | 71 | 76 | 74 |
| PolyPeptide Group | 69 | 79 | 65 | 76 | 63 | 76 | 71 |
| Genscript Biotech Corporation | 66 | 61 | 66 | 72 | 57 | 76 | 66 |
| Sino Biological Inc. | 54 | 68 | 49 | 47 | 67 | 55 | 57 |
| PeptiDream Inc. | 44 | 50 | 59 | 42 | 46 | 58 | 50 |
| China Peptides Co. Ltd. | 58 | 52 | 40 | 51 | 43 | 46 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Evonik Industries AG
- Bachem Holding AG
- CSPC Pharmaceutical Group Limited
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Evonik Industries AG | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Bachem Holding AG | ◐ | ✓ | ✓ | ◐ | ✓ | ◐ |
| CSPC Pharmaceutical Group Limited | − | ✓ | ◐ | ◐ | ◐ | ◐ |
| PolyPeptide Group | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Genscript Biotech Corporation | − | − | ◐ | ◐ | − | ◐ |
| Sino Biological Inc. | ◐ | ◐ | ◐ | − | ◐ | − |
| PeptiDream Inc. | − | − | ◐ | − | − | − |
| China Peptides Co. Ltd. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Evonik Industries AG83
2Bachem Holding AG78
3CSPC Pharmaceutical Group Limited74
4PolyPeptide Group71
5Genscript Biotech Corporation66
6Sino Biological Inc.57
7PeptiDream Inc.50
8China Peptides Co. Ltd.48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Evonik Industries AGBachem Holding AG
Challenger2
Strong scale, closing on the leaders.
CSPC Pharmaceutical Group LimitedPolyPeptide Group
Contender2
Focused players with pockets of strength.
Genscript Biotech CorporationSino Biological Inc.
Niche2
Specialists in a single segment or region.
PeptiDream Inc.China Peptides Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Peptide Type in North America, then scale across Synthesis Peptide for Cosmetic Application Market — a $169M beachhead inside a $3.01B market.
Beachhead (SOM)$169Mobtainable near-term
Serviceable (SAM)$1.16Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Signal Peptides
Best fit — highest urgency & budget in Peptide Type.
Economic buyer77 fit
Carrier Peptides
Strong fit — clear ROI and a fast path to value.
End user66 fit
Neurotransmitter Inhibitor Peptides
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Peptide Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Formulation Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve17%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Peptide Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Synthesis Peptide for Cosmetic Application Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified25%
Evaluation11%
Closed-won6%
$16.9KCAC
$96KLTV
5.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Synthesis Peptide for Cosmetic Application Market is a durable-growth opportunity — $5.70B by 2033, compounding at 8.6%.
TAM · 2025$2.95Btoday
TAM · 2033$5.70Bforecast
CAGR8.6%2027–2033
Cumulative$37.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.70BTotal addressable market
SAM$2.04BServiceable available market
SOM$417MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.6% CAGR
Demand compounds through 2033, outpacing GDP across Peptide Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Peptide Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.70BLarge & growingTAM by 2033 at 8.6% CAGR
$2.04BServiceable nowreachable with today’s model
$417MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.45BBear5.6% CAGR
$5.70BBase8.6% CAGR
$7.30BBull11.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Synthesis Peptide for Cosmetic Application Market — a $6.64B market by 2033. Plan: grow share from 10.1% to 16.7%.
Market size · 2033$6.64Btotal addressable
Market CAGR8.7%2027–2033
Target share16.7%from 10.1% today
Revenue ambition$1.11Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.1% | 16.7% | On track |
| Revenue | $674M | $1.11B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 29.6% | 38.6% | On track |
| Customer retention | 85.2% | 94.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Peptide Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Peptide Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $164M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Peptide Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Synthesis Peptide for Cosmetic Application Market conversation — a $4.53B market you can size, segment and defend in minutes.
Market size · 2033$4.53Btotal opportunity
Growth3.6%CAGR to 2033
Addressable buyers1,778+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Peptide Type
Goal Grow share in Peptide Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 3 mopayback period
$80K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Evonik Industries AGBachem Holding AGCSPC Pharmaceutical Group LimitedPolyPeptide GroupGenscript Biotech CorporationSino Biological Inc.PeptiDream Inc.China Peptides Co. Ltd.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Synthesis Peptide for Cosmetic Application Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Synthesis Peptide for Cosmetic Application Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Consumer Goods · scroll →Energy-based Skin Tightening Products Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportNeurological Rehabilitation Gaming Systems Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportSandblasting Dental Cleaner Market
Market size, share, segmentation and regional forecast.
$858M market · 2025 base year
View reportBlister Prvention Products For Heels Shoes Sandals Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportPre Sterilized %2F Ready Use Primary Packaging Market
Market size, share, segmentation and regional forecast.
$907M market · 2025 base year
View reportIce Point Depilator Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportWorld Sanitary Napkin Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportCold Packaging Products Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportReachers Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportBrush Market
Market size, share, segmentation and regional forecast.
$384M market · 2025 base year
View reportSleep Head Cover Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportSleep Earplugs Market
Market size, share, segmentation and regional forecast.
$795M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.